Low-dose Radiotherapy + SINTILIMAB for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Dec 2023: Trial started, NCT06220552
  2. 24 Jan 2024: Trial registered, NCT06220552

The trials

NCT06220552: The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma

State
Under way
Phase
Phase 2
People
20 planned
Started
27 Dec 2023
Primary completion
30 Dec 2027
Arms
Low-dose Radiotherapy Combined With Sintilimab and Temozolomide
Results
None posted
  1. 27 Dec 2023: Trial started
  2. 24 Jan 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.